Cookie Settings

We use cookies to optimize our website. These include cookies that are necessary for the operation of the site, as well as those that are only used for anonymous statistic. You can decide for yourself which categories you want to allow. Further information can be found in our data privacy protection .


These cookies are necessary to run the core functionalities of this website and cannot be disabled.

Name Webedition CMS
Purpose This cookie is required by the CMS (Content Management System) Webedition for the system to function correctly. Typically, this cookie is deleted when the browser is closed.
Name econda
Purpose Session cookie emos_jcsid for the web analysis software econda. This runs in the “anonymized measurement” mode. There is no personal reference. As soon as the user leaves the site, tracking is ended and all data in the browser are automatically deleted.

These cookies help us understand how visitors interact with our website by collecting and analyzing information anonymously. Depending on the tool, one or more cookies are set by the provider.

Name econda
Purpose Statistics
External media

Content from external media platforms is blocked by default. If cookies from external media are accepted, access to this content no longer requires manual consent.

Name YouTube
Purpose Show YouTube content
Name Twitter
Purpose activate Twitter Feeds

Joint Immunotherapeutics Laboratory

Scientists from the DKFZ and from Bayer working bench-to-bench

In 2013, the German Cancer Research Center (DKFZ) and Bayer HealthCare (Bayer) extended their successful strategic research alliance in search of novel cancer therapeutics by a new focus on immune-oncology and a joint laboratory.
The joint lab is located at DKFZ, and scientists from the DKFZ and from Bayer work bench-to-bench in mixed teams to develop novel treatment options in the area of immune-oncology. The joint lab is managed by a Scientific Head, an Associate Head, and two joint DKFZ-Bayer Committees.
The partners jointly invest up to €2.5 million per year, in projects in the field of immunotherapy on the base of established structures of their existing collaboration. This includes joint review processes of individual projects and decisions on resource allocation. The joint laboratory accommodates a mixed DKFZ-Bayer team of up to 12 staff members (scientists and technicians) and works on a portfolio of 4-7 projects at a time. The rights to the research results are shared equally between the partners.
For questions, please contact the DKFZ-Bayer Alliance Manager.


to top
powered by webEdition CMS